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Abstract
We demonstrate that the angiotensin-converting enzyme inhibitors enalapril and captopril inhibit the transport of D-Phe-
L-Gln into PepT1-expressing Xenopus oocytes and into rat renal cortical brush border membrane vesicles (BBMV). The
kinetics of inhibition are competitive. Enalapril and captopril are not substrates for PepT2 (Boll et al., Proc. Natl. Acad. Sci.
93 (1996) 284^289). Therefore we conclude that in rat renal cortical BBMV this neutral dipeptide is transported via
PepT1. ß 1998 Elsevier Science B.V. All rights reserved.
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PepT1 and PepT2 are proton-coupled oligopeptide
transporters responsible for the transport of di- and
tripeptides, in particular across the brush border
membrane of certain epithelia. The lower a⁄nity
PepT1 isoform was originally cloned from rabbit
small intestine [2], the higher a⁄nity isoform PepT2
from human kidney [3]. Northern blot analysis using
rat tissue has shown that, as well as being expressed
in the small intestine, PepT1 message is also found in
the kidney cortex [4]. In contrast, Northern blot
analysis with rat PepT2 has shown its mRNA to be
located predominantly in renal medulla, to a mark-
edly lesser extent in renal cortex and not in the in-
testine [5].
A unique property of these peptide transporters is
their extremely broad substrate speci¢city. As well as
transporting all naturally occurring di- and tripep-
tides (potentially 202 dipeptides and 203 tripeptides)
a number of therapeutically active molecules which
mimic the structure of an oligopeptide are also sub-
strates, e.g. L-lactam antibiotics [2] and the angioten-
sin-converting enzyme (ACE) inhibitors [6]. Under-
standing the mechanism of the absorption of these
molecules both in the small intestine and kidney has
obvious implications in the oral absorption and
clearance of these drugs.
The ACE inhibitor captopril was ¢rst demon-
strated to be a substrate for the intestinal peptide
transporter by Hu and Amidon [6]; subsequently
enalapril was also shown to be a substrate [7]. It is
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not surprising that these molecules are substrates for
the peptide transporter as chemically they resemble
the structure of a di- and tripeptide respectively (Fig.
1a). More recently Boll et al. [8] have shown that 10
mM captopril and enalapril inhibit the transport of
the L-lactam antibiotic cephadroxil into Xenopus lae-
vis oocytes expressing the cloned rabbit transporter
PepT1. However, of considerable interest was their
later ¢nding that in a similar experiment using PepT2
expressing X. laevis oocytes they did not observe an
interaction between this isoform of the peptide trans-
porter and the ACE inhibitors; cephadroxil trans-
port into PepT2 expressing oocytes was not inhibited
by either 5 mM enalapril or captopril [1].
In our laboratory we routinely use a preparation
of brush border membrane vesicles (BBMV) ob-
tained from rat renal cortex as a model system in
which to study proton-coupled oligopeptide trans-
port. Our kinetic data [9] are consistent with peptide
transport through a single saturable system that
obeys Michaelis-Menten kinetics. However, the ques-
tion has often arisen as to whether this system is
PepT1 or PepT2. In this study we have exploited
the di¡erent recognition of the ACE inhibitors by
PepT1 and PepT2 to address this question. The abil-
ity of the ACE inhibitors enalapril maleate (here
after referred to as enalapril) and captopril to inhibit
dipeptide transport in rat renal BBMV and X. laevis
oocytes expressing rabbit PepT1 has been examined.
Brush border membrane vesicles were obtained
from rat renal cortex by standard double magnesium
precipitation [10]. Transport studies were performed
using radiolabelled hydrolysis resistant dipeptides
(custom synthesised by Cambridge Research Bio-
chemicals, UK) under initial rate conditions (2 s or
4 s) at 37‡C using standard rapid ¢ltration as de-
scribed [9,11]. Brie£y membrane vesicles were resus-
pended in a high potassium solution containing the
potassium ionophore valinomycin (100 mM K-gluc-
onate, 20 mM D-mannitol, 0.1 mM MgSO4, 80 mM
Tris-HEPES pH 7.4, valinomycin 20 Wg/mg protein)
and the transport reaction commenced by the addi-
tion of 20 Wl of vesicles (12.5 mg/ml) to 80 Wl of
incubation medium (100 mM Na-gluconate, 20 mM
D-mannitol, 0.1 mM MgSO4, 80 mM Tris-MES pH
5.5) containing the labelled dipeptide (0.42 WM) and
the appropriate concentration of ACE inhibitor (0^
20 mM). The composition of the media was such
that on mixing, an inwardly directed pH gradient
(pHout=5.5, pHin=7.4) was imposed with membrane
potential clamped inside negative. The reaction was
terminated after the appropriate time by the addition
of 5 ml of ice-cold stop solution (150 mM NaCl, 50
mM MgSO4, 30 mM D-mannitol, 5 mM Tris-MES
pH 5.5) followed by rapid ¢ltration and 2U5 ml
further washes. The radiolabel associated with the
¢lters was measured by liquid scintillation counting.
X. laevis oocytes were obtained from mature fe-
male frogs and collagenased (Type 1A, Sigma) in
a nominally calcium free solution (80 mM NaCl,
2 mM KCl, 1 mM MgCl2, 5 mM HEPES pH 7.6)
for 30 min before being manually defolliculated and
maintained in modi¢ed Barth’s solution at 17‡C. Oo-
cytes were injected the day after isolation with 25 ng
rabbit PepT1 cRNA or an equivalent volume of
water and transport studies were performed 3^5
days post injection as described previously [12].
Brie£y oocytes (¢ve) were placed in 100 Wl of me-
dium (95 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1
mM MgCl2, 20 mM Tris-HEPES pH 5.5) containing
radiolabelled dipeptide (0.42 WM) and the appropri-
ate concentration of ACE inhibitor (0^20 mM).
After 1 h oocytes were removed and washed with
5U1 ml ice-cold Barth’s solution. Radiolabel associ-
ated with individual oocytes was measured by liquid
scintillation counting after disruption with 2% so-
dium lauryl sulphate.
Transport of the neutral dipeptide D-Phe-L-Gln
into PepT1 expressing Xenopus oocytes is clearly in-
hibited by enalapril and captopril (Fig. 1a) at a single
high concentration of 20 mM thus con¢rming the
¢ndings of Boll et al. [8]. When this experiment
was repeated using rat renal BBMV an identical ob-
servation was made (Fig. 1b) thus providing evidence
for the ¢rst time that enalapril and captopril interact
with the isoform of the proton-coupled oligopeptide
transporter present in these renal cortical BBMV.
This inhibition was explored further to establish
the a⁄nity for binding of captopril and enalapril in
the two experimental systems. The concentration de-
pendence of inhibition of D-Phe-L-Gln was studied
over the concentration range 0^20 mM in both the
BBMV and the PepT1 expressing oocyte prepara-
tions. An example of the data obtained is shown in
Fig. 2 and from Michaelis-Menten kinetics the a⁄n-
ity constant Ki could be calculated (Table 1). Kinetic
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analysis of data by Michaelis-Menten kinetics for a
single system was performed using Inplot. The data
analysed were mediated transport only, i.e. after sub-
traction of non-mediated transport (which is de¢ned
by uptake of labelled peptide remaining in the pres-
ence of 20 mM unlabelled dipeptide). The a⁄nity
constants for captopril and enalapril are 4.0 þ 1.0
mM and 1.1 þ 0.3 mM respectively in renal BBMV
and 8.7 þ 0.9 mM and 4.3 þ 0.2 mM in PepT1 ex-
pressing Xenopus oocytes. These values for renal
cortical BBMV fall within the range seen previously
using small intestine (e.g. [6,13^15]). In each system
enalapril binds with higher a⁄nity to the oligopep-
tide transporter than captopril which is consistent
with other published data using intestinal BBMV
[14].
It is of interest that for a given ACE inhibitor the
Ki for inhibition of peptide transport is always some-
what smaller when the measurement is made in
BBMV compared to the Xenopus oocyte expression
system; the di¡erence for enalapril and captopril is
2^4-fold and we have made similar observations pre-
viously using other substrates [16]. Possible explana-
tions include di¡erences in the imposed electrochem-
ical driving force in the two experimental systems
and thermodynamic e¡ects resulting from transport
being studied at di¡erent temperatures. The possibil-
ity that in the BBMV another system may be work-
ing in parallel with PepT1, e.g. PepT2, is unlikely as
an explanation since the measured di¡erence in a⁄n-
ity between the two systems (2^4-fold) is over an
order of magnitude smaller than the di¡erence in
measured substrate a⁄nity observed previously for
cloned PepT1 and PepT2 (50-fold); thus the Km for
cephadroxil transport in PepT1 expressing Xenopus
oocytes is 1.1 mM [8] while for translocation of the
same substrate through PepT2 it is 24 WM [1]. Con-
Fig. 1. Enalapril and captopril inhibition of tracer dipeptide in-
£ux. Control (no ACE inhibitor present), enalapril and capto-
pril (20 mM ACE inhibitor present). (a) PepT1 expressing
X. laevis oocytes, pHout = 5.5. Data points are mean þ S.E.M.
(two preparations of oocytes, ¢ve oocytes per preparation)
where transport into control (H2O-injected) oocytes has been
subtracted. (b) Rat renal BBMV, pHout = 5.5, pHin = 7.4 and
membrane potential clamped inside negative. Data points are
mean þ S.E.M. (two vesicle preparations, three estimates per
preparation) corrected for non-mediated transport (approx.
10%) by subtraction of labelled transport remaining in the pres-
ence of 20 mM unlabelled dipeptide.
Fig. 2. Concentration dependence of enalapril and captopril in-
hibition of mediated D-Phe-L-Gln in£ux into renal BBMV.
Enalapril (0^10 mM, circle), captopril (0^20 mM, triangle).
Data points are mean þ S.E.M. (triplicate estimates from repre-
sentative vesicle preparations). Solid line is best ¢t of data to
Michaelis-Menten kinetics. Calculated inhibition constants (Ki)
for enalapril and captopril are 1.3 mM and 3.0 mM respec-
tively.
BBAMEM 70847 4-8-98
C.S. Temple, C.A.R. Boyd / Biochimica et Biophysica Acta 1373 (1998) 277^281 279
sistent with the small di¡erence in a⁄nity we observe
between our two experimental systems are the data
of Terada et al. [17] and Saito et al. [4]. In each study
the transport of L-lactam antibiotics through cloned
rat PepT1 was measured and depending on the ex-
pression system used (Xenopus oocytes or LLC-PK1
cells) a 2-fold di¡erence in a⁄nity was observed.
In this study the Ki measurements in each system
were also performed in the presence of unlabelled D-
Phe-L-Gln (Ki app, Table 1) in order to investigate the
nature of the inhibition. It can be seen for each ACE
inhibitor, in both experimental systems, that the Ki
in the presence of unlabelled dipeptide (Ki app) was
greater than in the absence of unlabelled dipeptide
(Ki, Table 1), e.g. in PepT1-expressing oocytes the Ki
(in the absence of unlabelled D-Phe-L-Gln) was
8.7 þ 0.9 mM and increased to 15.2 þ 0 mM in the
presence of 1 mM unlabelled D-Phe-L-Gln (Ki app).
Qualitatively a shift of the Ki in this direction is
characteristic of competitive inhibition [18]. Note
that the shift in the observed Ki, in each system,
for each ACE inhibitor, was in the range 1.5^2-
fold. The concentration of unlabelled peptide used
in each case was equivalent to the previously deter-
mined Km so quantitatively if the mechanism of in-
hibition were competitive a doubling of the observed
Ki is predicted. We conclude that our data support
this mechanism and indicate that ACE inhibitor and
dipeptide compete for the same binding site on
PepT1. The competitive inhibition seen in this study
supports the ¢nding of Swaan et al. [15] (who ob-
served that enalapril competitively inhibited cepha-
lexin transport in an intestinal Ussing chamber prep-
aration) but is in contrast to the published data of
Yuasa et al. [13] (who found that enalapril non-com-
petitively inhibited the transport of the aminocepha-
losporin cephradine in rabbit intestinal BBMV).
Table 1
Inhibition constants (Ki, mM) and apparent inhibition constants (Ki app, mM) for enalapril and captopril inhibition of tracer D-Phe-L-
Gln in£ux into renal BBMV and PepT1 expressing oocytes
Unlabelled D-Phe-L-Gln (mM) Enalapril Captopril
Renal BBMV 0 Ki 1.1 þ 0.3 4.0 þ 1.0
0.21 Ki app 1.7 þ 0.1 8.1 þ 1.0
PepT1 expressing oocytes 0 Ki 4.3 þ 0.2 8.7 þ 0.9
1 Ki app 6.5 þ 0.2 15.2 þ 0
Ki values calculated in the absence (tracer labelled dipeptide only) of unlabelled dipeptide. Ki app values were calculated in the presence
of unlabelled D-Phe-L-Gln (with tracer labelled dipeptide) at the indicated concentrations (equivalent to the Km measured previously
for the dipeptide in each system). Ki and Ki app values were calculated from Michaelis-Menten kinetics as described in the text. Data
points are mean þ S.E.M. (n = 2).
Fig. 3. Enalapril and captopril inhibition of charged tracer di-
peptide in£ux into renal BBMV: (a) D-Phe-L-Glu (anionic) and
(b) D-Phe-L-Lys (cationic). Control (no ACE inhibitor present),
enalapril and captopril (20 mM ACE inhibitor present). Data
points are mean þ S.E.M. (triplicate estimates from representa-
tive vesicle preparations) corrected for non-mediated transport
by subtraction of labelled transport remaining in the presence
of 20 mM unlabelled substrate dipeptide.
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Interest has arisen recently regarding the mecha-
nism whereby PepT1 is able to transport di¡erently
charged dipeptides. We previously demonstrated that
the stoichiometry of proton-peptide cotransport in
rat renal BBMV was variable and depended on the
net charge carried by the substrate, i.e. the proton-
peptide coupling ratio for anionic (D-Phe-L-Glu),
neutral (D-Phe-L-Ala) and cationic (D-Phe-L-Lys)
dipeptides was 2:1, 1:1 and 0:1 respectively [11].
Subsequently the stoichiometry for neutral (Gly-
Ala) and anionic (Gly-Glu) dipeptides has been con-
¢rmed in PepT1-expressing Xenopus oocytes [19].
However, in this latter paper the transport of the
cationic dipeptide (Gly-Lys) was found to be pH
dependent with a coupling ratio of 1:1. One possible
explanation for the di¡erence observed is that in re-
nal BBMV D-Phe-L-Lys is transported through a
di¡erent system (e.g. PepT2). However, Fig. 3 shows
that the transport of both the anionic dipeptide D-
Phe-L-Glu and the cationic dipeptide D-Phe-L-Lys
in renal BBMV is inhibited by both enalapril and
captopril providing evidence that in this system
both these charged peptides are transported by
PepT1. The di¡erence in the estimated coupling ratio
for D-Phe-L-Lys in renal cortical BBMV and Gly-
Lys in PepT1-expressing Xenopus oocytes therefore
awaits explanation.
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